Cargando…

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

Immune-checkpoint inhibitors (ICIs) have widened the therapeutic scenario of different cancer types. Phase I/II trials have been designed to evaluate the role of ICIs both as single agents and in combination in neuroendocrine neoplasms (NENs), but as yet no randomized controlled phase III trials hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bongiovanni, Alberto, Maiorano, Brigida Anna, Azzali, Irene, Liverani, Chiara, Bocchini, Martine, Fausti, Valentina, Di Menna, Giandomenico, Grassi, Ilaria, Sansovini, Maddalena, Riva, Nada, Ibrahim, Toni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155858/ https://www.ncbi.nlm.nih.gov/pubmed/34067837 http://dx.doi.org/10.3390/ph14050476

Ejemplares similares

Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review
por: Bocchini, Martine, et al.
Publicado: (2020)

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
por: Severi, Stefano, et al.
Publicado: (2017)

(177)Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials
por: Bongiovanni, Alberto, et al.
Publicado: (2022)

Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis
por: Bongiovanni, Alberto, et al.
Publicado: (2020)

Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age
por: Bongiovanni, Alberto, et al.
Publicado: (2018)

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas
por: Recine, Federica, et al.
Publicado: (2017)

BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study)
por: Recine, Federica, et al.
Publicado: (2019)

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
por: Bongiovanni, Alberto, et al.
Publicado: (2015)

Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line
por: Miserocchi, Giacomo, et al.
Publicado: (2018)

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors
por: Liverani, Chiara, et al.
Publicado: (2023)

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents
por: De Vita, Alessandro, et al.
Publicado: (2017)

Primary leiomyosarcoma of the bone: a case report and a review of the literature
por: Recine, Federica, et al.
Publicado: (2017)

Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas
por: Miserocchi, Giacomo, et al.
Publicado: (2021)

Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy
por: Recine, Federica, et al.
Publicado: (2022)

Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by (18)fluorocholine PET/CT and its comparison with (68)gallium-DOTATOC PET/CT: Case report and review of the literature
por: Bongiovanni, Alberto, et al.
Publicado: (2017)

What is the role of checkpoint inhibitors in neuroendocrine neoplasms?
por: Al-Toubah, Taymeyah, et al.
Publicado: (2020)

First prospective data on breast cancer patients from the multicentre italian bone metastasis database
por: Bongiovanni, Alberto, et al.
Publicado: (2021)

Grading of Neuroendocrine Carcinomas: Correlation of (68)Ga-PET/CT Scan with Tissue Biomarkers
por: Liverani, Chiara, et al.
Publicado: (2018)

The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient‐derived primary culture case series in tridimensional and zebrafish models
por: De Vita, Alessandro, et al.
Publicado: (2021)

mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model
por: Spadazzi, Chiara, et al.
Publicado: (2019)

Comment on ‘Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: A nationwide Italian survey’ by Alice Indini et al.
por: Bongiovanni, Alberto, et al.
Publicado: (2020)

Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives
por: Vanni, Silvia, et al.
Publicado: (2022)

Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis
por: Ranallo, Nicoletta, et al.
Publicado: (2022)

ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations
por: Debonis, Silvia Angela, et al.
Publicado: (2021)

Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas
por: De Vita, Alessandro, et al.
Publicado: (2021)

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues
por: Gallo, Marco, et al.
Publicado: (2021)

Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms
por: La Rosa, Stefano
Publicado: (2021)

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
por: Maiorano, Brigida Anna, et al.
Publicado: (2021)

A case of metachronous double primary neuroendocrine cancer in pancreas/ileum and uterine cervix
por: Sisti, Giovanni, et al.
Publicado: (2012)

Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms
por: Liu, Man, et al.
Publicado: (2022)

Imaging presentation of pancreatic neuroendocrine neoplasms
por: Ciaravino, Valentina, et al.
Publicado: (2018)

Comparison of Anti–Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Update on Histological Reporting Changes in Neuroendocrine Neoplasms
por: Bräutigam, Konstantin, et al.
Publicado: (2021)

New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
por: Fortunati, Emilia, et al.
Publicado: (2022)

Circulating hsa-miR-5096 predicts (18)F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors
por: Bocchini, Martine, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
por: Bongiovanni, Alberto, et al.
Publicado: (2021)

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas
por: De Vita, Alessandro, et al.
Publicado: (2016)

DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
por: Yao, James, et al.
Publicado: (2022)

Histopathology of gastrointestinal neuroendocrine neoplasms
por: Hirabayashi, Kenichi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_iv3mju4askokjifcksv8fo1sp6